Rituximab Monotherapy for EBV-HLH and CAEBV

Clinical trial NCT05384743 · UNKNOWN

Trial details

NCT number: NCT05384743
Sponsor: Beijing Friendship Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Secondary Hemophagocytic Lymphohistiocytosis Chronic Active Epstein-Barr Virus Infection

Start date: 2022-02-01
Primary completion: 2024-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.